These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
867 related articles for article (PubMed ID: 10404830)
1. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830 [TBL] [Abstract][Full Text] [Related]
2. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688 [TBL] [Abstract][Full Text] [Related]
3. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175 [TBL] [Abstract][Full Text] [Related]
4. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Sabuncu T; Arikan E; Tasan E; Hatemi H Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944 [TBL] [Abstract][Full Text] [Related]
6. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [TBL] [Abstract][Full Text] [Related]
7. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874 [TBL] [Abstract][Full Text] [Related]
8. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790 [TBL] [Abstract][Full Text] [Related]
10. New perspectives in medical management of hyperprolactinemia. Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Sileo F; Ferrari L; Stroppa S; Gualteroni L; Pagani G Endocrinol Exp; 1990 Mar; 24(1-2):159-66. PubMed ID: 2361458 [TBL] [Abstract][Full Text] [Related]
11. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824 [TBL] [Abstract][Full Text] [Related]
12. Cabergoline in the treatment of acromegaly: a study in 64 patients. Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544 [TBL] [Abstract][Full Text] [Related]
13. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458 [TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia: pathophysiology and management. Verhelst J; Abs R Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552 [TBL] [Abstract][Full Text] [Related]
15. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285 [TBL] [Abstract][Full Text] [Related]
16. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684 [TBL] [Abstract][Full Text] [Related]
17. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081 [TBL] [Abstract][Full Text] [Related]
18. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732 [TBL] [Abstract][Full Text] [Related]
19. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Motta T; de Vincentiis S; Marchini M; Colombo N; D'Alberton A Fertil Steril; 1996 Feb; 65(2):440-2. PubMed ID: 8566276 [TBL] [Abstract][Full Text] [Related]
20. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]